Ready, set, prescribe? Doctors detail why they'll deploy Biogen's new Alzheimer's drug—or not

At the Washington University School of Medicine in St. Louis, the phone lines were “blowing up” Monday.

Alzheimer's disease patients and family members were calling about Biogen and Eisai's Aduhelm, approved just hours before, asking whether they could get on a list for treatment, said Erik Musiek, M.D., associate professor of neurology.